"Cisco (NASDAQ: CSCO), the bellwether company when it comes to performance in the tech industry, is hanging tough," says growth stock expert Toby Smith.

In his ChangeWave Investing he explains why "investors should own this stock before the economy shifts into a higher gear." Here's his review.

"As a true dominator, Cisco is beautifully positioned in several long-term secular trends including cloud computing and data center build-outs, unified communications, web-based video and telepresence.

This post is part of a seven article report -- Food for thought: Best bets in food & beverage stocks.

"Customers are trading down to McDonald's (NYSE: MCD) from higher-end restaurants," says growth stock expert Toby Smith in his ChangeWave Investing.

The fast food operator is also a buy from Bill Martin, who adds, the company continues to serve up solid results. In his BullMarket.com advisory, he reviews the stock's recent quarter.

First, Toby Smith explains, "Given the endless parade of depressing economic news, it's no wonder that most people have lost their appetite for food -- if not altogether, then at least for the finer dining.

"Our proprietary ChangeWave Alliance survey -- ongoing pols of thousands of individuals and investors in various industries and professions -- just 5% of respondents said they would spend more at restaurants, which is unchanged from the all-time low.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"If there ever was an opportunity to move energy efficiency strategies into the top-tier of national and industrial policy, it's now," says Toby Smith, referring to President-elect Obama's stated focus on renewable energy.

In his industry-leading ChangeWave Investing, which focuses on isolating emerging, long-term investment trends, he states, "The question isn't really if solar companies will benefit, but when." As a favorite idea for 2009, he looks to SunPower Corp. (NASDAQ: SPWRA).

"President-elect Obama seems to be the right person to push energy-efficiency initiatives through -- especially since he is preparing a massive stimulus program that will be unleashed soon after his inauguration on Jan. 20.

"The core of Obama's economic policy appears to be a strategy to transform the United States into an economy mostly powered by renewable and low-carbon energy generation by mid-century. This includes everything from solar to natural gas to nuclear.

Holiday retails sales may have been even worse than expected. It is hard to think why that would be a surprise. Consumer confidence numbers for December hit an all-time low. How does the retail industry get people that depressed to shop?

According to Bloomberg, "Holiday sales probably decreased 2.3 percent and traffic dropped 16 percent during November and December, ShopperTrak RCT Corp. estimated."

The numbers are misleading and may make people think that the holidays were not so bad for stores. After all, a drop of 2% can't be that bad. That figure does not take into account the fact that many chains and individual stores cut prices over 50%. The potential profit on the items which were cut that much may have disappeared. As a matter of fact, some companies probably took losses on parts of their inventories so they would not have items on their shelves that they could not sell at all after the first of the year.

The other issue is that while sales may have dropped 2.3% across the industry, that number was significantly worse at some chains. According to data from ChangeWave, consumers planned to make drastic cuts in spending at Sears (NASDAQ:SHLD), Macy's (NYSE:M), and Bed, Bath & Beyond (NASDAQ:BBBY). In other words, all retailers are not created equal. Some will show large losses for the fourth quarter, and are more likely to close stores and cut staff.

Other than that, everything was fine.

Douglas A. McIntyre is an editor at 247wallst.com.

"This is still a psychologically damaged market; take for example, what happened with VMware (NYSE: VMW) after its latest earnings announcement," notes Toby Smith in ChangeWave Investing.

"VMware recently reported that its fourth-quarter net income more than doubled on an 80% increase in revenue. Despite these excellent results, after-hours selling has plunged the shares lower by 25% to around $61.

"The culprit appears to be analysts' forecasts for an 82% increase in revenues. The buzz on the Street is that this miss signals stiffer competition in the virtualization space from Microsoft (NASDAQ: MSFT) and Oracle (NASDAQ: ORCL).

"However, during the conference call VMW management said customers have tried some competitors' products and told them that they see no reason to switch.

"This sell-off is similar to what recently happened to Apple (NASDAQ: AAPL) -- blowout performance followed by a hatchet job on the shares. As with Apple, we see this price drop in VMW as a great opportunity to establish a low cost-basis in the stock.

In referring to his recommended position in Cepheid (NASDAQ: CPHD), industry-leading biotech expert Michael Shulman jests, "To use a highly technical financial term: WooHoo! What a great quarter capped by a justifiably upbeat conference call."

Here, the editor of The ChangeWave Biotech Investor takes a look at the company, noting "I've been pounding the table for CPHD -- and this great quarter justifies my optimism."

"Cepheid develops and markets a diagnostic testing system called the GeneXpert that's a hardware platform for genetic tests of diseases that can be identified by their genetic code.

""There are several specific tests for this platform including MRSA, the killer staph infection that is typically found in hospitals, but is also spreading to other venues.

"In its latest quarrter, the company reported that revenues were $36.3 million, up 53% from Q3 2006. Total product sales were $34 million, up 50% and clinical product sales were $20.7 million, up 258%.

In its latest quarrter, the company reported that revenues were $36.3 million, up 53% from Q3 2006. Total product sales were $34 million, up 50% and clinical product sales were $20.7 million, up 258%.

"The GeneXpert system sales exploded! By the end of the quarter 1,376 GeneXpert System modules were installed in hospitals in the United States -- including 77 in VA hospitals, up by 51 modules in Q3 and representing a 79% share of the VA market.